Project Grant R43OD034180
- This $788,406 project grant from the National Institutes of Health National Institute of Allergy and Infectious Diseases, under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund the development of a sensitive, direct reading bioaerosol detection platform to quantify airborne pathogens such as SARS-CoV-2. Aerosol Devices Inc. will integrate their gentle condensation-growth capture sampler, which concentrates intact, viable virus particles into a small liquid volume...
- This $295,308 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), will support the development and validation of a novel class of scanning probe microscopy (SPM) probes for rapid identification of infectious disease agents. The awardee, Actoprobe LLC, aims to dramatically improve the sensitivity and spatial resolution of scanning...
- This SBIR Phase I project, funded by the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program, aims to develop a rapid diagnostic test for sepsis-causing pathogens in plasma samples using available digital PCR hardware. The $298,646 award to Anvil Diagnostics Inc., located in Cambridge, MA, will support the creation of a test that can comprehensively identify and quantify pathogens from small blood volumes, a critical capability for diagnosing sepsis...
- The National Science Foundation (NSF), under its Engineering program (CFDA 47.041), awarded a $429,832 Project Grant to the University of Massachusetts (UMass) to develop a novel method for rapid and sensitive detection of nucleic acids such as DNA and RNA. The main objectives of the 5-year project are to: Determine the nanomechanoelectrical transduction principle of nucleic-acid nanostructures tethered to a graphene transistor and oscillating in an electric field. Achieve rapid,...
- This Project Grant award of $432,834 was provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) with a performance period from April 15, 2025 to March 31, 2028. The objective is to develop an enzyme-free, label-free quantitative microarray technology to accurately measure and quantify small nucleic acid targets such as microRNA in the attomolar range for applications like liquid biopsy. The research...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award for $275,000 will support the development of a plasmonic nanopore sensor device for quality control of adeno-associated viruses (AAVs) used in gene therapy. The proposed device will enable accurate characterization of AAV payload (single-stranded DNA, double-stranded DNA, or empty) at low, pre-scale-up concentrations to optimize formulations. The project aims to demonstrate the...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $354,570 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Case Western Reserve University to develop a cost-effective, user-friendly point-of-care diagnostic tool for detecting HIV and hepatitis B virus (HBV) co-infection. The project aims to create a microchip platform utilizing color-encoded beads coated with antibodies to capture vital biomarkers, including HIV-1 RNA, HBV...
- This National Science Foundation (NSF) Partnerships for Innovation - Research Partnerships (PFI-RP) project grant, CFDA #47.084, provides $549,649 to the University of Rochester to advance the development of a novel membrane-based sensor technology for the rapid and specific detection of infectious pathogens in biofluids. The project aims to integrate the membrane sensor into a hand-operated microfluidic device with a colorimetric readout, and demonstrate the generalizability of the approach...
- This National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase I award to RT Microdx Inc. provides $274,362 to develop a novel molecular diagnostic platform for detecting respiratory diseases like strep throat. The platform aims to provide laboratory-quality accuracy for at-home use by non-healthcare professionals. Key technical objectives include optimizing the sensitivity of the platform's pH-sensitive polymer detection mechanism and ensuring robust performance at...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award supports the development of a novel device that can rapidly and automatically extract pathogen DNA from whole blood samples to enable faster diagnosis of sepsis. The $274,858 award to New England Hemolytics, Inc., with a project period from September 1, 2024 to February 28, 2025, will fund the testing and optimization of this technology across common sepsis-causing pathogens. The...
DYE-LOADED NANOPARTICLE PLATFORM FOR RAPID AND SENSITIVE VIVARIUM PATHOGEN DETECTION - PROJECT SUMMARY THIS PROPOSAL DEVELOPS KEY ASPECTS OF AN ULTRASENSITIVE PATHOGEN DETECTION SYSTEM FOR RODENT ANIMAL HEALTH SURVEILLANCE AND IS IN RESPONSE TO THE NIH FOA PAR-21-225 TO DEVELOP NOVEL TOOLS AND DEVICES FOR ANIMAL RESEARCH FACILITIES AND TO SUPPORT THE CARE OF ANIMAL MODELS. THE GOAL OF THE PROJECT IS TO DEVELOP A MICROFLUIDIC DEVICE FOR RAPID AND INEXPENSIVE PATHOGEN DETECTION DIRECTLY FROM AN ANIMAL OR FROM SOILED BEDDING. THE DEVICE WILL BE USED CAGE-SIDE AND WILL COMPLEMENT CURRENT RODENT HEALTH MONITORING PROGRAMS WHICH ARE DESIGNED TO MONITOR ROOMS OR CAGE RACKS QUARTERLY. USE OF THE DEVICE WILL ENCOURAGE RAPID OUTBREAK MITIGATION AND RESOLUTION AS WELL AS CONFIRM HEALTH STATUS FOR ANIMAL IMPORTATION. THE ADVANTAGES OF THE PLATFORM WILL BE SPECIFICITY, SIMPLICITY, SPEED, AND SENSITIVITY IN A "3RS" CONSISTENT APPROACH. THE SPECIFICITY OF THE DETECTION SYSTEM RELIES ON DNA HYBRIDIZATION OF A SYNTHETIC OLIGONUCLEOTIDE DESIGNED SPECIFICALLY FOR THE PATHOGEN OF INTEREST WITH DNA CAPTURED FROM INFECTIOUS AGENTS DIRECTLY FROM THE RODENT OR FROM BEDDING SAMPLES. THE DETECTION STEP WILL BE RAPID SINCE THE DNA HYBRIDIZATION WILL NOT RELY ON CYCLIC AMPLIFICATION OF THE DNA BUT INSTEAD WILL SHIFT THE SENSITIVITY REQUIREMENTS TO RELEASE OF DYE FROM MESOPOROUS SILICA NANOPARTICLES USING PH-DEPENDENT DYE RELEASE. IN THIS PHASE I PROPOSAL, THE KEY ASPECTS OF THE PLATFORM WILL BE OPTIMIZED AND TESTED FOR FEASIBILITY IN 4 AIMS. FIRST, THE PATHOGEN DNA PREPARATION PROTOCOL WILL BE ESTABLISHED USING A BACTERIAL AND VIRAL DNA SOURCE, AND THE LIMIT OF PATHOGEN DETECTION QUANTIFIED FOR DNA COLLECTION. SECOND, THE SYNTHETIC OLIGONUCLEOTIDE THAT SERVES IN PATHOGEN DETECTION WILL BE OPTIMIZED AND BOUND TO MAGNETIC NANOPARTICLES. THIRD, INTERNAL PORES AND EXTERNAL SURFACES OF MESOPOROUS SILICA NANOPARTICLES (MSNPS) WILL BE DIFFERENTIALLY LABELLED SO THAT THE INTERNAL SURFACES ARE SATURATED WITH REVERSIBLY BOUND DYE MOLECULES WHILE THE EXTERNAL SURFACES ARE COATED WITH DNA THAT WILL HYBRIDIZE WITH THE PATHOGEN SPECIFIC DETECTION OLIGONUCLEOTIDE. LASTLY, PROOF OF FEASIBILITY OF THE PLATFORM WILL BE TESTED BY COMBINING THE PATHOGEN DETECTION AND ULTRASENSITIVE PH-RESPONSIVE DYE RELEASE ASPECTS. THE INNOVATION OF THIS PLATFORM IS IN THE USE OF DNA SECONDARY STRUCTURE TO PROVIDE PATHOGEN SPECIFICITY, THE USE OF MSNPS DESIGNED SPECIFICALLY FOR SATURATED DYE LOADING WITH PH-SENSITIVE DYE RELEASE, AND THE USE OF DNA HYBRIDIZATION TO PHYSICALLY BIND THE SPECIFICITY AND SENSITIVITY FEATURES TOGETHER, ALLOWING ENRICHMENT OF THE DETECTION COMPLEXES WITH THE USE OF MAGNETIC NANOPARTICLES.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 4/21/25 | ||
| Not listed | $236.1k | 8/16/23 |